Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
NCI-CCC Tumor Board Question
•
NCI-CCC Lymphoma Tumor Board Question
•
City of Hope
How would you manage a patient with a recent diagnosis of advanced DLBCL (non-GCB subtype) who has baseline grade 3 neuropathy?
Answer from: Medical Oncologist at Community Practice
Avoid neurotoxic agents. Substitute pola; avoid vincristine.
Sign In
or
Register
to read more
30982
Related Questions
In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?
How would you manage a frail patient with GCB DLBCL who is unable to complete R-CHOP but has moderate residual disease?
How would you manage a patient w/ blastoid variant MCL given data w/ all the current BTKi regimens TRIANGLE, BOVEN, and TRAVERSE
What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?
Does the recent publication of EPCORE FL-1 (Epcoritamab + R2) change your preferred 2L SOC for R/R FL?
Do you utilize ctDNA-based MRD testing after frontline chemotherapy for DLBCL?
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
What is your management approach for CAR-T induced motor neurologic deficits (cyclophosphamide/IVIG/steroids, etc.) and any prophylactic approach to an early, rapid rise in absolute lymphocyte count post CAR-T infusion?
How would you manage a stage IE Burkitt lymphoma with stable disease after three cycle of DA-R-EPOCH?
What criteria would you consider to select patients for 20 Gy consolidative RT in DLBCL/HGBL?